DSM-Firmenich AG (DSFIR)
Euronext Amsterdam · Netherlands · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 108.95 |
|---|---|
| 52-week range | 55.22 – 109.85 |
| Return, 1 month / 3 months | +11.4% / +33.1% |
| Return, 1 year / 3 years | +50.9% / +50.2% |
| Trend | Uptrend |
| RSI (14) | 70 |
| Volatility (1 year) | 30.8% |
| Worst drawdown (1 year) | -24.8% |
| Average daily value traded | 60.92M EUR |
| Dividend yield | 2.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
DSM-Firmenich is a maker of ingredients used in nutrition, health and beauty products. The company supplies vitamins, flavours, fragrances and specialty ingredients to food and beverage producers, personal care brands and animal nutrition customers. It serves manufacturers and consumer goods companies across many countries. The business is based in Switzerland and its stock is traded on the Dutch exchange in Amsterdam, reflecting a European base with a broad international customer reach.
DSM-Firmenich AG trades under the code DSFIR on the Euronext Amsterdam in Netherlands, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
DSM-Firmenich AG (DSFIR) trades on the Euronext Amsterdam in Netherlands. It last closed at EUR 108.95 on 27 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 9 of 109 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 50.9% and over the last three months it rose 33.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Amsterdam
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 98 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 42.4% | ||
| From 52-week high | -0.7% | ||
| Momentum | 92 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 33.1% | ||
| 6-month return | 77.2% | ||
| 12-month return, skipping the last month | 35.4% | ||
| Stability (higher is calmer) | 52 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.8% | ||
| Liquidity | 90 · Strong | Trades actively. | |
| Average daily value traded | 60.92M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 22 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.5% | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.3% |
|---|---|
| 1 month | +11.4% |
| 3 months | +33.1% |
| 6 months | +77.2% |
| 1 year | +50.9% |
| 3 years | +50.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 97.40 / 76.52 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.28 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 May 2026 | CHF 2.5000 |
| 8 May 2025 | CHF 2.5000 |
| 9 May 2024 | CHF 2.5000 |
| 3 Jul 2023 | CHF 1.6000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Amsterdam; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.